2B70:F:F-iShares NASDAQ US Biotechnology UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 5.898

Change

-0.05 (-0.79)%

Market Cap

USD 0.52B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.10 (+0.39%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 117.80B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.14 (+0.26%)

USD 92.18B
SXR8:F iShares Core S&P 500 UCITS ETF..

+2.58 (+0.49%)

USD 85.13B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.07 (+0.30%)

USD 75.40B
EUNL:F iShares Core MSCI World UCITS ..

-0.08 (-0.08%)

USD 72.04B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 56.70B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 55.70B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.58 (+0.60%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.75 (+0.79%)

USD 51.63B

ETFs Containing 2B70:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.51% 41% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.51% 39% F 46% F
Trailing 12 Months  
Capital Gain 4.80% 42% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.80% 40% F 48% F
Trailing 5 Years  
Capital Gain 42.31% 60% D- 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.31% 59% D- 51% F
Average Annual (5 Year Horizon)  
Capital Gain 6.44% 68% D+ 67% D+
Dividend Return 6.44% 67% D+ 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.60% 41% F 72% C
Risk Adjusted Return 44.11% 65% D 71% C-
Market Capitalization 0.52B 62% D 50% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.